Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 9011913
Use of functionalized magnetic nanoparticles in cancer detection and treatment
granted -
US 9005649
Methods for making controlled delivery devices having zero order kinetics
granted -
US 9005599
Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
granted -
US 9005648
Inorganically surface-modified polymers and methods for making and using them
granted -
US 9006399
Anti-OX40 antibodies and methods of using the same
granted -
US 9005185
Nanochanneled device and related methods
granted -
US 9005964
Endodermal progenitor cells
granted -
US 9000131
Antibodies that neutralize botulinum neurotoxins
granted -
US 8999988
Protein kinase inhibitors
granted -
US 8999934
Treatment of astrocytes-tumor cells inhibitors of endothelin receptors
granted -
US 8999349
HMGB1-derived peptides enhance immune response to antigens
granted -
US 8999294
Nanoparticles for use in tumor diagnosis and therapy
granted -
US 8999705
Bifidobacterial gene sequences and their use
granted -
US 9000179
Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs)
granted -
US 8992894
Oral stain remover and oral composition
granted -
US 8993719
Methods and compositions related to mutant Kunitz domain I of TFPI-2
granted -
US 8993552
Compositions and methods for treatment of leukemia
granted -
US 8993251
Genes from 20q13 amplicon and their uses
granted -
US 8992906
Compositions and methods for engraftment and increasing survival of adult muscle stem cells
granted -
US 8992886
Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
granted -
US 8993758
Substituted quinoxalines and uses thereof
granted -
US 8986736
Method for delivering particulate drugs to tissues
granted -
US 8986701
Enzyme prodrug cancer therapy selectively targeted to tumor vasculature and methods of production and use thereof
granted -
US 8989847
Method of measuring propulsion in lymphatic structures
granted -
US 8987332
Methods of treating inflammatory conditions
granted -
US 8987309
Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles
granted -
US 8987294
Small molecule inhibitors of the Ξ±4-paxillin interaction
granted -
US 8987192
Potent and selective mediators of cholesterol efflux
granted -
US 8987189
Treating hepatitis C virus infection
granted -
US 8986737
Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth
granted -
US 8980258
Bispecific single chain Fv antibody molecules and methods of use therof
granted -
US 8980838
Cyclized peptidomimetic small molecule inhibitors of the WDR5 and MLL1 interaction
granted -
US 8980836
Method of treating degenerative disorders of the nervous system
granted -
US 8981046
Synthetic cell platforms and methods of use thereof
granted -
US 8980907
Dendrimer conjugates
granted -
US 8980899
Methods of inhibiting Ire1
granted -
US 8980608
High molecular weight heparosan polymers and methods of production and use thereof
granted -
US 8979831
Thermochemical ablation system using heat from delivery of electrophiles
granted -
US 8975243
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
granted -
US 8975293
Epigenetic co-repressors of the gamma-globin gene and methods of using same
granted -
US 8974792
Internalizing erbB2 antibodies
granted -
US 8975014
Fluorescence detection of poison oak oil
granted -
US 8974810
Tissue graft compositions and methods for producing same
granted -
US 8975029
Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
granted -
US 8969287
Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry
granted -
US 8969296
TGFP-CAP peptide and its uses
granted -
US 8969077
Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
granted -
US 8968786
Formation of stable submicron peptide or protein particles by thin film freezing
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory